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Abstract We present the first case of pituitary carcinoma oc-
curring in a patient with a succinate dehydrogenase subunit B
(SDHB) mutation and history of paraganglioma. She was ini-
tially treated for a glomus tumour with external beam radio-
therapy. Twenty-five years later, she was diagnosed with a
non-functioning pituitary adenoma, having developed
bitemporal hemianopia. Recurrence of the pituitary lesion
(Ki-67 10% and p53 overexpressed) occurred 5 years after
her transsphenoidal surgery, for which she underwent two
further operations followed by radiotherapy. Histology
showed large cells with vacuolated clear cytoplasm with pos-
itive immunostaining for steroidogenic factor 1 (SF1) and
negative staining for pituitary hormones. Four years after the
pituitary radiotherapy, twometastatic deposits were identified:
a foramen magnum lesion and an intradural extra-medullary
cervical lesion at the level of C3/C4. There was also
significant growth of the primary pituitary lesion with associ-
ated visual deterioration. A biopsy of the foramen magnum
lesion, demonstrating cells with vacuolated, clear cytoplasm
and positive SF1 staining confirmed a pituitary carcinoma, for
which she was commenced on temozolomide chemotherapy.
There was dramatic clinical improvement after three cycles
and reduction in the size of the lesions was observed following
six cycles of temozolomide, and further shrinkage after 10
cycles. The plan is for a total of 12 cycles of temozolomide
chemotherapy. SDH mutation-related pituitary tumours have
an aggressive phenotype which, in this case, led to metastatic
disease. SF1 immunostaining was helpful to identify the tissue
origin of the metastatic deposit and to confirm the pituitary
carcinoma.
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Abbreviations
SDHB Succinate dehydrogenase subunit B
SF1 Steroidogenic factor 1
MGMT O6 methyl guanine methytransferase
MSH6 DNA mismatch repair protein
MEN Multiple endocrine neoplasia
VHL von Hippel Lindau
Introduction
The co-occurrence of pituitary adenoma (PA) and paraganglioma
is a rare event. Such association was first described in 1952 [1]
but it is only recently that the underlying genetic mutations have
been elucidated in some of the cases [2–5]. Mutations in one of
the five succinate dehydrogenase (SDHA-D, SDHA2F) genes
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are most common followed by mutations in MEN1 and RET
genes [3–8].
Pituitary carcinoma is defined as a tumour of adenohy-
pophyseal cells that causes cranio-spinal or systemic metasta-
ses. Pituitary carcinoma is uncommon, accounting for about
0.12% of adenohypophyseal tumours [9, 10], 6% of invasive
adenomas [11], and with a reported incidence in Europe lower
than 0.4 × 100,000 [12]. About 20% of pituitary carcinomas
are clinically non-functioning. In such cases, unless the loca-
tion of the metastatic deposits cause symptoms, patients may
remain asymptomatic and the metastases are only discovered
incidentally or at autopsy.
We describe the first patient with an SDHB mutation who
developed a paraganglioma and a clinically non-functioning
gonadotroph carcinoma. Metastases from the initial adenoma
occurred over a decade after the first transsphenoidal surgery.
Case Presentation
This patient presented in 1980 at the age of 28 years with
unilateral deafness. She was diagnosed with a glomus tumour
of the right ear based on a CT-scan and she was treated with
external beam radiotherapy. At that time, her past medical and
family history were otherwise unremarkable. In 2005, she
developed a bitemporal hemianopia. A magnetic resonance
imaging (MRI) demonstrated an intra and suprasellar lesion
that had features consistent with a pituitary adenoma. She had
no clinical evidence of pituitary hormone excess or deficiency,
suggesting the lesion was clinically non-functioning. Urinary
metanephrines were normal. She underwent transsphenoidal
surgery with gross total resection of the lesion. Her visual
fields fully recovered. The lesion was reported as an ‘atypical’
adenoma (WHO 2004 classification) [13] by an experienced
neuropathologist but the original slides and paraffin blocks of
the primary tumour were not available for review.
The pituitary lesion recurred 5 years later. She underwent a
second transsphenoidal operation, which was followed by
transcranial debulking and fractionated rapid arc radiotherapy
(50.4 Gy) a few months later. This recurrent tumour was doc-
umented in a recent study [5]. Briefly, the lesion showed ac-
inar and lobular architecture and was composed of large cells
with vacuolated, clear cytoplasm, at times mimicking
physaliferous cells of chordoma (Fig. 1a). Immunostains for
Fig. 1 Histology of the recurrent pituitary lesion. The recurrent pituitary
lesion shows acinar and lobular architecture and is composed mostly of
large cells with clear, vacuolated cytoplasm reminiscent of physaliferous
cells of chordoma (a—HE, ×40); tumour cells show nuclear expression of
SF1 (b—immunoperoxidase, ×40, mouse anti-SF1 (sc-393,592) at dilu-
tion 1:100) top left insert shows SF1 nuclear expression in normal adrenal
and lower right insert shows SF1 expression in FSH positive pituitary
adenoma; up to 15% of neoplastic cells are positive for Ki-67 (c—
immunoperoxidase, ×20, DAKO, monoclonal at dilution 1:200) and
abou t 5% show s t rong nuc lea r express ion of p53 (d—
immunoperoxidase, ×20, DAKO, clone D07 at dilution 1:200). Ki-67
and p53 were quantified at the magnification of ×40 in the three fields
showing the highest number of positive cells. The number of positive
cells and the overall number of neoplastic cells was counted manually
by tagging in each field, averaged and represented as a percentage of Ki-
67 or p53 expressing cells against the whole number of neoplastic cells
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pituitary hormones were negative whilst neoplastic cells
showed nuclear expression of steroidogenic factor 1 (SF1)
(Fig. 1b) [14]. The Ki-67 labelling index was 15%, p53 was
overexpressed in about 5% of tumour cells (Fig. 1c,d ) and the
immunoreaction for MGMT was negative suggesting silenc-
ing of the gene. About 60% of tumour cells showed nuclear
expression of MSH6. Expression of SDHB was faint to nega-
tive in neoplastic cells [5].
Genetic testing revealed a heterozygote pathogenic mis-
sense mutation in the SDHB gene (c.587G>A; p.Cys196Try,
MIM 185470) [12–15].
The adenoma remained stable for the following 4 years.
However, a surveillance MRI identified an extra-axial lesion
in the foramen magnum with extension into the left hypoglos-
sal canal (Fig. 2a). Upon review of previous MRI scans, the
lesion was visible 2 years before, but grew substantially dur-
ing the interval period. A further intradural extra-medullary
cervical lesionwas also evident at the level of C3/C4 (Fig. 2b).
Both pituitary and cerebellar lesions were avid on FDG PET,
but non avid on MIBG. Contrast enhancement and uptake of
FDG and MIBG of the spinal lesion was conversely low.
A diagnostic biopsy from the foramen magnum lesion was
taken. Following the procedure, the patient developed seizures
and expressive dysphasia. A CT-scan demonstrated hydro-
cephalus. She improved after the insertion of a ventriculo-
peritoneal shunt with some residual receptive dysphasia and
right sided hemianopia. A MRI performed the following year
demonstrated growth of both the suprasellar and the foramen
magnum lesions, causing complete loss of vision and some
distortion of the medulla. Gallium PETconfirmed progressive
disease and she developed Charles Bonnet syndrome (com-
plex visual hallucinations in visually impaired patients). She
was started on a 12 cycle course of temozolomide treatment
(200 mg/m2 for 5 days, every 28 days). After three cycles she
showed dramatic clinical improvement in her expressive and
receptive dysphasia as well as in her visual acuity with stabil-
ity on MRI. Following six and then ten temozolomide cycles,
MRI demonstrated slight reduction in the size of the lesions.
Pathological examination of the metastatic deposit demon-
strated features similar to those of the recurrent pituitary ade-
noma. The neoplastic cells had the same degree of
vacuolisation.Mitotic count was lower than 1 × 10 high power
field. The neoplastic cells were positive for cytokeratin
MNF116, cytokeratin CAM5.2, synaptophysin and the pitui-
tary transcription factor SF1, and they were negative for pitu-
itary hormones, TTF-1, EMA, S-100 protein, inhibin, GFAP,
brachyury, common α-subunit and oestrogen receptor. Ki-67
expression was 10% and about 4–5% showed intense nuclear
expression of p 53. Similar to the sellar recurrence, tumour
cells were negative for MGMT and about 70% expressed
MSH6 (Fig. 3).
We note that in 2007, the patient’s sister at the age of 51
years developed an anaplastic oligodendroglioma (WHO
grade III) and died of the disease in the same year.
Immunostaining for SDHB showed normal expression in the
tumour cells.
Discussion
We have documented the first case of pituitary carcinoma
occurring in a patient with an SDH mutation. Pituitary carci-
nomas rarely occur in genetic syndromes; examples of pitui-
tary carcinoma patients withMEN1mutations have been doc-
umented [15–17], whilst AIP, PRKAR1A, DICER1 and
GPR101 mutations have not been associated with metastatic
spread to date.
Pituitary adenomas occurring in patients with SDH muta-
tions or adenomas bearing somatic mutations are more often
lactotroph adenomas followed by gonadotroph adenomas and
somatotrophinomas [5].
Vacuolated, clear cytoplasm was the hallmark of the pitui-
tary tumour and posterior fossa metastasis and the fact that it
was present in both lesions indicates that vacuoles are genuine
features of the tumour rather than an artefact. Our previous
work documented vacuolated cytoplasm in SDH-mutated
Fig. 2 Radiological images of
the pituitary lesion and metastatic
deposits. a Sagittal section of
MRI pituitary post gadolinium
showing suprasellar mass and
extra-axial metastatic deposit in
the posterior fossa with extension
into the left hypoglossal canal. b
MRI axial sequence post
gadolinium showing the
intradural extra-medullary
cervical metastatic deposit at the
level C3/C4
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adenomas but not in patients with pituitary adenomas and
phaeochromocytomas due to MEN1 or VHL genes. This evi-
dence suggests that vacuoles are due to inactivation of the
SDH complex but the mechanism leading to their formation
remains unclear. In our experience, vacuoles range from small
and multiple to large, occupying most of the cytoplasm and
mimic signet-ring cells of metastatic adenocarcinoma, clear
cells of renal cell carcinoma or physalipherous cells of
chordoma. In an Sdhb (+/−) animal model, giant
mitochrondria were shown in the pituitary tumours, which
may account for the cytoplasmic vacuoles [4], but we were
unable to show positive mitochrondrial markers in human
cases in our previous study [5].
Although not limited to SDH-related pituitary tumours,
widespread clear cell changes in pituitary samples should
alert the pathologists and prompt further investigations.
Immunostaining with SDHA and SDHB antibodies is a
valuable diagnostic tool to screen adenomas prior to
requesting genetic analysis. Gill et al. [8] investigated a
large cohort of adenomas and identified 1/309 patient
whose adenoma was negative for SDHA and SDHB.
Genetic analysis revealed two somatic inactivating muta-
tions in SDHA in this single case.
The primary and recurrent adenohypophyseal tumour in
our patient had features of an atypical adenoma. Initially de-
fined as adenomas with uncertain malignant potential, the def-
inition of atypical adenoma remains controversial. Two recent
studies have attempted to provide more reproducible criteria
for predicting the outcome of pituitary adenomas. Mitotic ac-
tivity, increased Ki-67 labelling index and overexpression of
the oncoprotein p53 remain helpful for a diagnosis of adeno-
ma with high risk of recurrence. Trouillas et al. [18] proposed
a staging system where pathological criteria are integrated
with extension and invasion to the surrounding structures.
The pituitary tumour sample from the second transsphenoidal
operation from this patient (4 years before diagnosis of meta-
static disease) would belong to the 2b group of the Trouillas
classification. A more recent study based on data from the
German Pituitary Adenoma Registry suggested cut off values
for Ki-67 equal to or >4% and p53 equal to or >2% and
indicated that these two markers are more reliable and repro-
ducible than mitotic count for the diagnosis of high-risk ade-
noma [19].
Metastatic deposits in our patient occurred almost a decade
after the diagnosis of PA. Studies have attempted a distinction
between pituitary carcinomas that show rapidly aggressive
course and those showing a more indolent behaviour [20,
21]. These latter lesions account for the majority of cases
and their behaviour is similar to invasive adenoma except
for presence of metastases. Patients’ survival can be long with
reports documenting up to 25 years. In contrast, those present-
ing as a malignant appearing lesion showmultiple recurrences
in a short time from onset, metastatic spread occurs early and
have rapidly fatal progression with a survival that is often
shorter than 1 year [20]. The underlying genetic makeup of
the two groups is unknown.
We think it is unlikely that the initial radiotherapy (RT) for
the paraganglioma caused the pituitary tumour, or contributed
to its progression, as the pituitary fossa was well outside the
fields of irradiation. Our patient had an excellent clinical re-
sponse to temozolomide and her disease burden is now stable,
having completed ten of the planned 12 cycles of temozolo-
mide since the discovery of the two metastatic deposits.
Following the original observation of positive response of pi-
tuitary tumours to temozolomide [22], several studies have
advocated the use of this drug to control invasive adenomas
and carcinomas. Overall, the benefit of temozolomide is mod-
est but still significant given the natural history of pituitary
Fig. 3 Histology of the metastatic deposit. Pathological features of the
metastatic deposit are similar to the sellar recurrent tumour; neoplastic
cells shows clear vacuolated cytoplasms; one mitosis is present in this
field (a—HE, ×40); the immunoreactions for MGMT is negative in
neoplastic cells; endothelial cells demonstrate normal nuclear
expression (b—immunoperoxidase, ×20, Chemicon, monoclonal
antibody at dilution 1:500); tumour cells show nuclear expression of
MSH6 (c immunoperoxidase, ×20 using Roche clone 44 and antigen
retrieval with CC1 and Optiview detection kit)
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carcinoma [10, 22–26]. Haematological toxicity is a complica-
tion that may require dose reduction and seldom withdrawal of
the agent. Low-level MGMT immunoexpression was correlat-
ed with a favourable response [27, 28]. However, no constant
association was found between MGMT promoter methylation
and response [28, 29]. In a recent study, 10/13 (77%)
temozolomide-treated ‘atypical’ adenomas or carcinomas
responded, either completely or partially [30]. Six cases
(46%) r ecu r r ed a f t e r i n i t i a l r e sponse . MGMT
immunoexpression had no relation with the response to temo-
zolomide, whilst immunoexpression of MSH6 was proven to
correlate significantly with the response [30–32]. In the mis-
match repair pathway, base mismatches are detected by the
heterodimers of MSH2 and MSH6, which assist another het-
erodimeric complex of MLH1 and PMS2 [33]. Mismatch re-
pair pathway stimulates DNA damage-induced G2 checkpoint
and apoptosis during DNA synthesis. It was suggested that the
inactivation of MMR is associated with tolerance to the cyto-
toxic effects of alkylating agents [34, 35].
In conclusion, we have documented the first pituitary car-
cinoma in a patient with a germline mutation of the SDHB
gene and paraganglioma. Differential diagnosis between pitu-
itary carcinoma and other clear cell tumours in our patient was
challenging given the unusual features of the lesion.
Immunostaining for the SF1 was helpful to identify the tissue
origin of the metastatic deposit.
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